| General information | |
| ACovPid: | ACoVP100256 |
| Trivial Name: | HR2-18 |
| Amino Acids Sequence: | IQKEIDRLNEVAKNLNESLIDLQELGK |
| Length: | 27 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Source Description: | From the heptad repeat region 2 of spike glycoprotein of SARS-CoV |
| Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Inhibition Value Type: | EC50 |
| Inhibitory Effect: | 5.52 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | MTT assay |
| Assay Description: | BJ01 strain (SARS-CoV wild-type virus) was a gift of Beijing Genomics Institute. Two hundred TCID50 of wild-type SARS-CoV were co-incubated with 50 µl peptides of different concentrations at 37 °C for 30 min. The mixture was then transferred to 96-well plates, eight wells for each dilution. After incubation for 60 h, a MTT assay was then performed as described previously(PMID: 8450240). Briefly, 10 µl dimethylthiazol diphenyltetrazolium (MTT) (5 mg/ml) (Sigma–Aldrich) was added to each well and incubated for 4 h. The medium in each well was then replaced with 100 µl DMSO and the plates stayed at room temperature for 10 min for color development before being read by a BioRad Model 550 ELISA reader (using a test wavelength of 570 nm and a reference wavelength of 630 nm). |
| Anti-CoV activity in vivo: | |
| Reference: | 15184046 |
| Comment: | |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | ACoVP100246 ACoVP100250 ACoVP100252 ACoVP100242 ACoVP100247 |